Market Exclusive

Analyst Activity – Leerink Swann Reiterates Market Perform on ACADIA Pharmaceuticals (NASDAQ:ACAD)

Analyst Ratings For ACADIA Pharmaceuticals (NASDAQ:ACAD)

Today, Leerink Swann reiterated its Market Perform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD).

There are 3 hold ratings, 10 buy ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) is Buy (Score: 2.77) with a consensus target price of $47.54 per share, a potential 26.47% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) has insider ownership of 22.25% and institutional ownership of 97.10%.

Recent Trading Activity for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version